AstraZeneca's Evusheld Revenue Stream To Dry Up Soon
As FDA Withdraws Authorization Of COVID-19 Therapy
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
You may also be interested in...
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
Supplemental Filings: Gene Therapy Harmonization Moving Ahead; US FDA’s COVID-19 EUA Authority Hanging Around
Peter Marks suggests the need for a ‘compromise’ on gene therapy. Elizabeth Sadove looks towards an extended tenure for COVID products under EUAs.
NICE says that limitations in the evidence for Evusheld make it difficult to produce a reliable cost-effectiveness estimate.